An Official Website of the United States Government
Company Information:
Name:
ADVANTAGENE, INC
Address:
ADVANTAGENE, INC
440 Lexington St
Auburndale, MA
440 Lexington St
Auburndale, MA
Located in HUBZone:
No
Woman-Owned:
No
Minority-Owned:
No
URL:
N/A
Phone:
N/A
Award Totals:
Award List:
Combination of GM-CSF with TKR gene therapy
Award Year / Program / Phase:
2003 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Madhu Chhikara
Award Amount:
$100,000.00
Abstract:
DESCRIPTION (provided by applicant): Combined gene therapy (Herpes Simplex Virus Thymidine Kinase + Anti-herpetic Prodrug) and radiation therapy (TKR therapy) is a novel approach in the armamentarium against cancer. This radio-gene therapy combination creates a new spatial co-operation whereby two… More
Clinical study of AdV-tk radiogene therapy for glioma
Award Year / Program / Phase:
2004 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Estuardo Aguilarcordova
Award Amount:
$758,386.00
Abstract:
DESCRIPTION (provided by applicant): Malignant gliomas have a very poor prognosis with median survival measured in months rather than years. It is a disease with great need of novel therapeutic approaches. Within cancer gene therapy the use of adenoviral vectors to deliver HSV-tk (AdV-tk) has… More
Clinical study of GMCI in Pancreatic Cancer
Award Year / Program / Phase:
2006 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Estuardo Aguilarcordova
Award Amount:
$747,384.00
Abstract:
DESCRIPTION (provided by applicant): Pancreatic adenocarcinoma is the fourth leading cause of cancer deaths in the US; with less than one-year median survival, it accounts for approximately 30,000 diagnoses and deaths per year. Multimodality therapy, including surgery, radiation and chemotherapy,… More
Improved system for producing adenoviral vectors
Award Year / Program / Phase:
2007 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Douglas J. Jolly
Award Amount:
$213,871.00
Abstract:
First generation non-replicative adenoviral vectors show promise as anti-cancer agents and as prophylactic vaccines. Current methods for manufacturing these vectors use either the 293 cell line or the PER.C6 cell line. These producer cells provide comple
mentary E1a and E1b viral function in the… More
Clinical and Immunologic Evaluation of ProstAtak for Prostate Cancer
Award Year / Program / Phase:
2007 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Estuardo Aguilarcordova
Award Amount:
$101,130.00
Abstract:
DESCRIPTION (provided by applicant): The main objective of this project is to develop a new therapeutic to improve the outcome for patients with intermediate-risk prostate cancer. The indication is a first-line adjuvant to be combined with radiation therap
y for prostate cancer. The desired outcomes… More
Clinical study of AdV-tk radiogene therapy for malignant glioma
Award Year / Program / Phase:
2007 / SBIR / Phase II
Agency:
HHS
Principal Investigator:
Estuardo Aguilarcordova
Award Amount:
$2,092,604.00
Abstract:
DESCRIPTION (provided by applicant): Malignant gliomas have a very poor prognosis with median survival measured in months rather than years. It is a disease with great need of novel therapeutic approaches. Within cancer gene therapy the use of adenovira
l vectors to deliver HSV-tk (AdV-tk) has… More
Clinical and Immunologic Evaluation of ProstAtak for Prostate Cancer
Award Year / Program / Phase:
2009 / SBIR / Phase II
Agency:
HHS
Principal Investigator:
Estuardo Aguilarcordova
Award Amount:
$7,226,591.00
Abstract:
DESCRIPTION (provided by applicant): The main objective of this project is to develop a new therapeutic to improve the outcome for patients with intermediate-risk prostate cancer. The indication is a first-line adjuvant to be combined with radiation therap
y for prostate cancer. The desired outcomes… More